ACADIA Pharmaceuticals Inc.

ACADNASDAQHealthcare● Active

$21.56

+$0.00(+0.02%)

Market Cap$3.7B

P/E Ratio—

52W High$28.35

52W Low$19.69

Avg Volume1.8M

Open$21.70

Beta0.83

Free Cash Flow Financials Revenue

ACADIA Pharmaceuticals Inc. (ACAD) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ACAD · free cash flow · updated Jun 8, 2026

Core FCF metrics

ACAD · FCF · TTM · margin & CAGR

Free cash flow was $105.1M for FY2025 (fiscal year ending 2025-12-31), down 33.1% year-over-year The FCF margin was 9.8%.

FY2025 Free Cash Flow$105.1M▼ -33.1% YoY

Trailing 12M (TTM)$212.4Mtrailing 4 quarters sum

FCF Margin9.8%$105.1M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ACAD · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$109.8M(5M)$105.1M▼ 33.1%9.8%

FY2024$157.7M(1M)$157.2M▲ +773.3%16.4%

FY2023$16.7M(40M)−$23.3M▲ +79.5%-3.2%

FY2022−$114.0M(0M)−$114.0M▲ +10.1%-22.1%

FY2021−$125.7M(1M)−$126.8M▲ +11.8%-26.2%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ACAD · P/FCF · FCF yield · FCF per share

ACADIA Pharmaceuticals Inc. (ACAD) trades at a FCF yield of 5.75% and a price-to-free-cash-flow ratio of 17.3x. FCF per share stands at $1.25, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

5.75%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$1.25

TTM FCF ÷ Shares Outstanding

Price / FCF

x17.3

Share Price ÷ FCF per Share

EV / FCF (TTM)

x16.3

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

ACAD · cash flow statement · operating / investing / financing

For FY2025, ACADIA Pharmaceuticals Inc. generated $109.8M in operating cash flow and spent 5M in capital expenditures, yielding $105.1M in free cash flow.

Operating Activities

+$109.8M

Cash from core business operations

2025-12-31

Investing Activities

−$302.6M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$49.9M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($109.8M) − |CapEx| (5M) = FCF ($105.1M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ACAD vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

ACADIA Pharmaceuticals Inc.YOU

ACAD

$105.1M-33.1%9.8%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

ACADIA Pharmaceuticals Inc. (ACAD) reported free cash flow of $105.1M for FY2025 (fiscal year ending 2025-12-31), down 33.1% year-over-year. The FCF margin was 9.8%.

Based on available data, ACADIA Pharmaceuticals Inc. has maintained positive free cash flow for at least 2 fiscal year(s). FCF peaked at $157.2M in FY2024.

ACADIA Pharmaceuticals Inc.'s FCF yield is 5.75% and price-to-FCF ratio is 17.3x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ACAD free cash flow · 8 questions

ACADIA Pharmaceuticals Inc. free cash flow was $105.1M for FY2025, down 33.1% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $212.4M.

ACAD free cash flowACAD FCFACAD FCF 2025ACAD free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · ACADIA Pharmaceuticals Inc. · ACADIA Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026